The Utility of Immune Checkpoint Inhibition in the Management of Resectable Non-Small Cell Lung Cancer
Louis Filipiak1, Koosha Paydary1, Mary Jo Fidler1
1Department of Medicine, Section of Hematology, Medical Oncology and Cell Therapy, Rush University Medical Center, Chicago, IL 60612, USA.
None:
Immune checkpoint inhibitors (ICIs) are approved in at least one line of therapy for most patients with advanced non-small cell lung cancer (NSCLC) without EGFR/ALK alterations and have improved survival for a subset of patients. Adjuvant, neoadjuvant, and perioperative therapy for resectable NSCLC carries the hope of more broadly increased cure rates for patients with resectable lung cancers. This review summarizes the current state of multimodality management, including ICIs, for resectable NSCLC. A literature search of PubMed and Scopus identified phase II and III clinical trials including ICIs in patients with resectable NSCLC. No level 1 evidence guides the clinician in choosing between the available neoadjuvant and perioperative approaches.
